TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2072147
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of etoposide (125 mg/m2/d)
Study: 28931149
Drug: B-GOS (2.7g
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-GOS (2.7g daily for 7-15 days)
Study: 22468907
Drug: Therapist adherence
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist adherence to concrete cognitive therapy techniques
Study: 12564664
Drug: Otic powder
Normalized name: Primadophilus Reuteri Probiotic Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otic powder (Auricularum)
Study: 7534331
Drug: Octreotide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (100 micrograms subcutaneously, twice daily for 4 weeks)
Study: 2361714
Drug: Rice water
Normalized name: CVS Electrolyte Solution with Zinc (Rice Water)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice water electrolytes solution
Study: 375343
Drug: BAY g
Normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY g 5421 (Acarbose) 50 mg
Study: 21890887
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 10 mg
Study: 21890887
Drug: Isobaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric bupivacaine 10 mg
Study: 21890887
Drug: Hypobaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypobaric bupivacaine 10 mg
Study: 18984669
Drug: Hyperinsulinemic euglycemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinemic euglycemic clamp with LPS (insulin infusion at 10 or 40 mU.m(‐2).min(‐1))
Study: 28393773
Drug: Dexmedetomidine (Dex)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (Dex) 0.5 μg/kg/h
Study: 24267363
Drug: Oral desensitization
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral desensitization (200 mL of cow's milk daily)
Study: 22122955
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) administered perorally after shooting
Study: 8895046
Drug: Nimodipine monotherapy
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine monotherapy
Study: 9790159
Drug: Nimodipine with
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine with carbamazepine augmentation
Study: 9790159
Drug: Nimodipine-carbamazepine combination
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine-carbamazepine combination
Study: 2561036
Drug: metoprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol (200 mg/die)
Study: 2561036
Drug: combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: combined therapy with atenolol (50 mg) and nifedipine (20 mg)
Study: 2561036
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg acebutolol and 20 mg nifedipine
Study: 2561036
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg atenolol and 10 mg enalapril
Study: 2561036
Drug: all treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: all treatments
Study: 21855244
Drug: Boswellia serrata
Normalized name: Boswellia Serrata
DrugBank: Indian frankincense (DB14275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boswellia serrata gum resin extracts (BSE) at a high dose of 4200 mg per day
Study: 17274236
Drug: Herbal mouthwash
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal mouthwash containing the pericarp extract of Garcinia mangostana L
Study: 23359265
Drug: Nevirapine 200
Normalized name: nevirapine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine 200 mg once-daily regimen
Study: 27849643
Drug: Diclofenac (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (100 mg)
Study: 8376274
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg)
Study: 27275104
Drug: Naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 mg)
Study: 26615516
Drug: Esmolol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (500 mcg/kg bolus 10 min before induction, followed by 200 mcg/kg/min infusion)
Study: 22954393
Drug: Half-dose tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose tirofiban (5 μg/kg bolus, 0.075 μg/kg/min infusion for 48 h)
Study: 22954393
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Standard-dose and Half-dose tirofiban)
Study: 20803038
Drug: Palliative therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative therapies
Study: 15168037
Drug: Eccentric exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eccentric exercise followed by a CHO-rich diet (> 10 g/kg body mass/24 h)
Study: 9853438
Drug: Topical recombinant
Normalized name: thrombin topical recombinant 5000 intl units topical powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical recombinant bovine basic fibroblast growth factor (rbFGF) 150 AU/cm2 daily
Study: 29723874
Drug: Warfarin (anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (anticoagulant continued)
Study: 29723874
Drug: Lower-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose edoxaban regimen (LDER) (anticoagulant continued)
Study: 8893110
Drug: Hydroxyzine 25
Normalized name: hydroxyzine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 25 mg tid
Study: 6148843
Drug: Dynamically oriented
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamically oriented supportive therapy (ST)
Study: 24439238
Drug: Day patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day patient treatment (DP) after 3 weeks of inpatient care
Study: 29222135
Drug: Inpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient treatment (IP)
Study: 22823994
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care treatment + SABR to all sites of known disease
Study: 22823994
Drug: Current standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current standard of care treatment
Study: 17460714
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily ramipril 10 mg
Study: 17460714
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily ramipril 5 mg
Study: 12475452
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone for 45 days
Study: 9972754
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (25-200 microg)
Study: 12676276
Drug: Calcium appetite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium appetite related to perturbed calcium metabolism
Study: 25556427
Drug: Metformin (500mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500mg Bid)
Study: 25556427
Drug: Megestrol (40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Megestrol (40mg daily)
Study: 23871290
Drug: Heparin thromboprophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin thromboprophylaxis
Study: 3545941
Drug: Co-trimoxazole twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole twice daily
Study: 24704505
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated tetravalent bovine-human reassortant rotavirus vaccine (BRV-TV)
Study: 15820074
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (intraoperative hypotonic peritoneal chemo-hyperthermia and early postoperative intraperitoneal chemotherapy)
Study: 15820074
Drug: Treatment groups
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment groups 1 and 2 (combined therapy and intraoperative chemotherapy)
Study: 12549803
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen (10 mg/kg/dose for three doses given at 24 hourly intervals)
Study: 12549803
Drug: Indomethacin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.2 mg/kg/dose for three doses given at 12 hourly intervals)
Study: 12549803
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen and Indomethacin
Study: 15662995
Drug: Albendazole 1200
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 1200 mg
Study: 7858933
Drug: MTC 40
Normalized name: MTC-DOX
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MTC 40 mg by nasal spray 2 h before chemotherapy, followed by the same dose at 4 h and 8 h (nasal spray)
Study: 2488281
Drug: Zidovudine (AZT);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (AZT); specific dosage and duration not mentioned
Study: 31073189
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) elements
Study: 28552257
Drug: Nebulized liposomal
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized liposomal amphotericin B (LAmB) maintenance therapy
Study: 28552257
Drug: Conventional strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional strategy without antifungal maintenance therapy
Study: 21348793
Drug: Cilostazol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (200 mg/day) for 8 weeks
Study: 19731700
Drug: Lifestraw Personal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestraw Personal water treatment device
Study: 15019322
Drug: Topical 0.05%
Normalized name: ingenol topical 0.05% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.05% cyclosporin A eyedrops
Study: 11262208
Drug: pyrimethamine‐sulfadoxine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: pyrimethamine‐sulfadoxine and 3 doses of artesunate
Study: 9272590
Drug: Hypoglycaemia (at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycaemia (at around 3 mmol l(‐1))
Study: 2459655
Drug: Bovine surfactant
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bovine surfactant treatment
Study: 2126475
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no surfactant treatment)
Study: 3563430
Drug: Sulfadiazine-trimethoprim combination
Normalized name: sulfadiazine / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadiazine-trimethoprim combination (500 mg + 150 mg) b.i.d. for 3 days
Study: 3563430
Drug: Sulfadiazine-trimethoprim combination
Normalized name: sulfadiazine / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadiazine-trimethoprim combination (500 mg + 150 mg) b.i.d. for 10 days
Study: 3563430
Drug: Pivmecillinam (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam (500 mg) t.i.d. for 3 days
Study: 28967984
Drug: SYM‐1219 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYM‐1219 2 g
Study: 27440710
Drug: Zoledronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoledronate (5 mg intravenously once per year)
Study: 27440710
Drug: Alendronate (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (70 mg orally once per week)
Study: 24458543
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy for Insomnia (CBT-I)
Study: 20524443
Drug: Nicomild‐2 Sugar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicomild‐2 Sugar Free Gum (2 mg pieces, 6.74%)
Study: 20524443
Drug: Nicorette Sugar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorette Sugar Free (2 mg pieces)
Study: 18514508
Drug: Exemestane 25mg
Normalized name: EXEMESTANE 25MG TAB
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane 25mg daily and celecoxib 400mg twice daily (group A)
Study: 18514508
Drug: Exemestane 25mg
Normalized name: EXEMESTANE 25MG TAB
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane 25mg daily (group B)
Study: 18514508
Drug: Letrozole 2.5mg
Normalized name: LETROZOLE 2.5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5mg daily (group C)
Study: 16769438
Drug: Interviewer‐Administered Questionnaire
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer‐Administered Questionnaire (IAQ)
Study: 28873075
Drug: Magnesium infusion
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium infusion
Study: 1495197
Drug: Cefdinir 3
Normalized name: cefdinir 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefdinir 3 mg/kg administered 1 hour before meal (fasting state)
Study: 23588865
Drug: 5 mg/ml
Normalized name: urea 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/ml (total 2 ml) esmolol
Study: 15166570
Drug: Morphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.1 mg
Study: 15166570
Drug: Morphine 0.3
Normalized name: ethylmorphine 0.32 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.3 mg
Study: 12002497
Drug: Intravenous regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous regional blockade (IVRB) with 15 mg of guanethidine in 30 ml of 0.5% prilocaine
Study: 12002497
Drug: Serial IVRB
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial IVRB with 30 ml of normal saline (control)
Study: 1965420
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of itraconazole given in one single day
Study: 1965420
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg once daily for three days
Study: 6802327
Drug: Slow-release aminophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release aminophylline (14 mg/kg twice daily)
Study: 30947585
Drug: Blinatumomab by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinatumomab by continuous infusion for 4 weeks in 6‐week cycles
Study: 30947585
Drug: Standard salvage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard salvage chemotherapy
Study: 9293649
Drug: Epidural butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural butorphanol 0.5 mg
Study: 9293649
Drug: Epidural butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural butorphanol 0.5 mg plus clonidine 75 micrograms
Study: 2825502
Drug: Fiber supplements
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber supplements (three different types)
Study: 24621255
Drug: Exenatide BID
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide BID (5 µg for 4 weeks, then 10 µg ongoing)
Study: 16398429
Drug: Shengmai injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shengmai injection (SI)
Study: 3059899
Drug: Theophylline at
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline at mean concentrations of 5.13, 12.07, and 18.6 micrograms/ml
Study: 26277887
Drug: pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pioglitazone 30 mg once daily
Study: 19604642
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine (22.2±2.0 mg/h/70 kg)
Study: 15456342
Drug: Intravenous anidulafungin
Normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous anidulafungin 50 mg/day
Study: 15456342
Drug: Oral fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fluconazole 100 mg/day
Study: 11552994
Drug: Post-heparin prophylaxis
Normalized name: Anthrax, post-exposure prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-heparin prophylaxis (4 months after delivery)
Study: 9522143
Drug: Prilocaine 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prilocaine 2% (6 mL)
Study: 9522143
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% (3 mL)
Study: 2483435
Drug: Ibopamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine (100 mg t.i.d.)
Study: 4423243
Drug: Permissively worded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permissively worded amnesia suggestions with hypnotic motivation
Study: 4423243
Drug: Authoritatively worded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Authoritatively worded amnesia suggestions with hypnotic motivation
Study: 17219155
Drug: Intracervical dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intracervical dinoprostone gel (0.5 mg every 6 h for a maximum of 24 h)
Study: 15650341
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy (0.625 mg conjugated estrogen)
Study: 6318353
Drug: Bi-Profenid 300
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bi-Profenid 300 mg
Study: 6318353
Drug: Oxyphenbutazone 400
Normalized name: oxyphenbutazone
DrugBank: Oxyphenbutazone (DB03585)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxyphenbutazone 400 mg
Study: 31868813
Drug: 16 weekly
Normalized name: Weekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 weekly sets per muscle group (G16)
Study: 31868813
Drug: 24 weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 weekly sets per muscle group (G24)
Study: 31868813
Drug: 32 weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 weekly sets per muscle group (G32)
Study: 16871748
Drug: Cimetidine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (3 x 200 mg + 400 mg after 12 h)
Study: 7624262
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg
Study: 9917431
Drug: Sn-mesoporphyrin (SnMP)
Normalized name: Sn Mesoporphyrin
DrugBank: Stannsoporfin (DB04912)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sn-mesoporphyrin (SnMP) 6.0 micromol/kg birth weight, single dose, intramuscular
Study: 8014496
Drug: Alternating combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating combination regimen of chronic ganciclovir-foscarnet therapy
Study: 29384322
Drug: Daily isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily isoflavone supplementation (50 mg/day aglycone daidzein and genistein) with two green kiwifruit
Study: 29384322
Drug: Daily isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily isoflavone supplementation (50 mg/day aglycone daidzein and genistein) alone
Study: 21392600
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin
Study: 10718203
Drug: Metrifonate (125-225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate (125-225 mg loading dose for 2 weeks, followed by 50-90 mg maintenance dose for 4 weeks)
Study: 29362276
Drug: Integrated medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated medicines management (IMM) intervention including medication reconciliation, review, counselling, medication list, and post-discharge calls.
Study: 25904041
Drug: BMS‐820836 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐820836 2 mg once daily for 14 days
Study: 25904041
Drug: BMS‐820836 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐820836 4 mg once daily for 14 days
Study: 21216314
Drug: Plans to
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Plans to increase vaccine purchases
Study: 21216314
Drug: Stocking all
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stocking all adult vaccines
Study: 8256309
Drug: Fermented milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented milk product (200 ml daily for six weeks)
Study: 26686960
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg/day)
Study: 23200931
Drug: Buprenorphine Transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine Transdermal System (BTDS) 10 μg/hour
Study: 23200931
Drug: Buprenorphine Transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine Transdermal System (BTDS) 20 μg/hour
Study: 20965447
Drug: Adjunctive TMS
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive TMS
Study: 11181472
Drug: Tezosentan 100
Normalized name: TEZOSENTAN
DrugBank: Tezosentan (DB06558)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezosentan 100 mg/h
Study: 458200
Drug: ADV‐4 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADV‐4 vaccine
Study: 19345067
Drug: TNFalpha-antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TNFalpha-antagonists
Study: 16960171
Drug: Tomato extract
Normalized name: TOMATO EXTRACT CONTAINING LYCOPENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato extract supplement drink (equivalent to 6 tomatoes)
Study: 9248875
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg lorazepam as needed every 30 min for 4 h
Study: 9248875
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg haloperidol as needed every 30 min for 4 h
Study: 23743961
Drug: Iron (II)
Normalized name: iron(II) sulfate
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron (II) sulfate (Fe2+), 5 mg Fe/kg/d
Study: 9279680
Drug: Heparin-surface-modified (HSM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-surface-modified (HSM) PMMA intraocular lenses
Study: 1948264
Drug: Proguanil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proguanil (200 mg/day) combined with sulfamethoxazole (1000 mg/day)